ArticleGland surgery2026
Perioperative outcomes and postoperative functional outcomes of robot-assisted radical prostatectomy for oligometastatic versus localized prostate cancer: a multicenter matched case-control study.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As treatment for oligometastatic prostate cancer (OmPCa) gains increasing attention, the safety of robot-assisted radical prostatectomy (RARP) in this patient population has sparked growing interest. This study aimed to compare the perioperative outcomes and postoperative functional outcomes of RARP between patients with OmPCa and those with localized prostate cancer (LPCa), and to evaluate the safety and feasibility of RARP in OmPCa patients. Methods: This multicenter, retrospective, case-control study included 100 OmPCa patients (defined as having ≤5 bone and/or lymph node metastases, excluding visceral metastases) who underwent RARP between March 2010 and December 2023 at five hospital centers in China. For comparison, 100 LPCa patients were matched 1:1 to the OmPCa group based on the surgical center and operative date. Perioperative and postoperative functional outcomes were compared between the two groups. Results: The OmPCa group exhibited significantly higher median preoperative prostate-specific antigen (PSA) levels (22.63 Conclusions: This study demonstrates that compared to LPCa patients, RARP does not increase the risk of perioperative adverse outcomes or postoperative functional decline in patients with OmPCa. This finding provides evidence for expanding the surgical indications for RARP in the treatment of OmPCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.